secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2026-09-08T12:09:26+00:00
Accession:  0001104659-26-105688
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics: ACCG-2671 SAD positive, aleniglipron 72-wk OLE up to 16.2% weight loss
--------------------------------------------------------------------------------

- ACCG-2671 SAD: 31 healthy adults, ~6-day half-life, no SAEs, 3.3% mean weight loss at Day 24 (10 mg), CTX-1 down ~60%.
- Aleniglipron 72-wk OLE: 11.6%/14.4%/16.2% weight loss for 45/90/120 mg arms; >1/3 of 90/120 mg cohorts >20% loss (35.9/40.5 lbs).
- Placebo crossover with 2.5 mg start: 9.0% (22.7 lbs) at 36 wks; <5% discontinuation due to AEs; improved GI tolerability.
- Phase 3 ACCOMPLISH-1 (3,600) and -2 (1,100) enrolling; topline 2H 2028. ACCG-2671 MAD topline 1H 2027.
- Q4 2026 readouts: body composition, T2DM, and SWITCH trial results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/0001104659-26-105688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-105688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer